JPS5585572A - Nn*phenoxyalkyl*imidazole compound - Google Patents

Nn*phenoxyalkyl*imidazole compound

Info

Publication number
JPS5585572A
JPS5585572A JP16138279A JP16138279A JPS5585572A JP S5585572 A JPS5585572 A JP S5585572A JP 16138279 A JP16138279 A JP 16138279A JP 16138279 A JP16138279 A JP 16138279A JP S5585572 A JPS5585572 A JP S5585572A
Authority
JP
Japan
Prior art keywords
phenoxyalkyl
imidazole compound
imidazole
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP16138279A
Other languages
English (en)
Other versions
JPS585197B2 (ja
Inventor
Edowaado Kurosu Piitaa
Piitaa Deitsukinson Rojiyaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10501705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5585572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPS5585572A publication Critical patent/JPS5585572A/ja
Publication of JPS585197B2 publication Critical patent/JPS585197B2/ja
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP54161382A 1978-12-13 1979-12-12 N−(フェノキシアルキル)イミダゾ−ル化合物 Expired JPS585197B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB48367/78N--- 1978-12-13
GB7848367 1978-12-13

Publications (2)

Publication Number Publication Date
JPS5585572A true JPS5585572A (en) 1980-06-27
JPS585197B2 JPS585197B2 (ja) 1983-01-29

Family

ID=10501705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54161382A Expired JPS585197B2 (ja) 1978-12-13 1979-12-12 N−(フェノキシアルキル)イミダゾ−ル化合物

Country Status (34)

Country Link
US (2) US4602016A (ja)
JP (1) JPS585197B2 (ja)
KR (1) KR830001243B1 (ja)
AR (1) AR227637A1 (ja)
AT (1) AT373879B (ja)
AU (1) AU517892B2 (ja)
BE (1) BE880584A (ja)
CA (1) CA1108137A (ja)
CH (1) CH644597A5 (ja)
CS (1) CS216517B2 (ja)
DD (1) DD147943A5 (ja)
DE (1) DE2950019A1 (ja)
DK (1) DK471479A (ja)
EG (1) EG14227A (ja)
ES (1) ES8101556A1 (ja)
FI (1) FI70888C (ja)
FR (1) FR2444031A1 (ja)
GB (1) GB2038821B (ja)
GR (1) GR73003B (ja)
HU (1) HU183016B (ja)
IE (1) IE49318B1 (ja)
IL (1) IL58917A (ja)
IT (1) IT1194900B (ja)
LU (1) LU81985A1 (ja)
NL (1) NL177749C (ja)
NO (1) NO153135C (ja)
NZ (1) NZ192360A (ja)
PH (1) PH15056A (ja)
PL (1) PL134005B1 (ja)
PT (1) PT70571A (ja)
SE (1) SE444937B (ja)
SU (1) SU878195A3 (ja)
YU (1) YU301879A (ja)
ZA (1) ZA796708B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58113178A (ja) * 1981-12-28 1983-07-05 Yamanouchi Pharmaceut Co Ltd 「お」−(1−イミダゾリル)アルキルオキシ(またはチオ)ベンゼン誘導体
JPH01125372A (ja) * 1988-09-12 1989-05-17 Yamanouchi Pharmaceut Co Ltd イミダゾリルアルキルオキシベンゼン誘導体

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350696A (en) * 1980-03-08 1982-09-21 Pfizer Inc. Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
DE3148291A1 (de) * 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4588732A (en) * 1982-12-21 1986-05-13 Ciba-Geigy Corporation Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
PH22076A (en) * 1983-08-25 1988-05-20 Daiichi Seiyaku Co Benzocycloalkane derivative
IT1212791B (it) * 1983-11-24 1989-11-30 Medea Res Srl Derivato imidazolico adattivita' vasodilatatrice ed antitrombotica, sua preparazione e composizioni farmaceutiche che lo contengono.
ES8601148A1 (es) * 1984-12-10 1985-11-16 Ferrer Int Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos.
US4894385A (en) * 1985-01-16 1990-01-16 Sankyo Company Limited Imidazole derivatives as inhibitors of TXA2 synthesis
SU1739848A3 (ru) 1986-01-28 1992-06-07 Санкио Компани Лимитед (Фирма) Способ получени производных тианафтена или их фармацевтически приемлемых солей
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
JPS63179840A (ja) * 1986-07-24 1988-07-23 Yamanouchi Pharmaceut Co Ltd 新規化学物質
EP0284892B1 (de) * 1987-04-03 1990-10-31 Cl Pharma Aktiengesellschaft Neue 2-Thienyloxyessigsäurederivate, ein Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE4204686A1 (de) * 1992-02-17 1993-08-19 Gruenenthal Gmbh Imidazolylphenolderivate, diese enthaltende arzneimittel sowie ein verfahren zur herstellung dieser verbindungen und arzneimitteln
AU2890899A (en) * 1998-03-13 1999-09-27 Pozen, Inc. Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
AU2003244913A1 (en) * 2002-07-09 2004-01-23 B.M.R.A. Corporation B.V. Pharmaceutical combination of a thromboxane A2 receptor antagonist and a COX-2 inhibitor
CA2534316A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-1
KR101275814B1 (ko) * 2006-06-23 2013-06-18 삼성에스디아이 주식회사 분산제 화합물 및 그의 제조방법
WO2009105140A2 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CN101811974B (zh) * 2010-04-15 2012-12-12 合肥医工医药有限公司 4-(3-(二甲氨基)丙氧基)-3,5-二甲氧基苯甲酸、其制法及医药用途
CN101851209B (zh) * 2010-06-21 2012-09-19 合肥医工医药有限公司 咪唑乙基香草酸醚、其制备方法及其医药用途
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
WO2023240378A1 (zh) * 2022-06-13 2023-12-21 南京医工医药技术有限公司 咪唑烷基香草酸醚衍生物及其用途
CN114736161B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑烷基香草酸醚衍生物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534061A (en) * 1967-12-04 1970-10-13 Parke Davis & Co N-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)-phenoxyalkyl pyrroles
US4085209A (en) * 1975-02-05 1978-04-18 Rohm And Haas Company Preparation and safening effect of 1-substituted imidazole metal salt complexes
US4078071A (en) * 1976-03-08 1978-03-07 Syntex (U.S.A.) Inc. Derivatives of substituted N-alkyl imidazoles
JPS5951943B2 (ja) * 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CHEM. SOC. PEVKIN 1=1975 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58113178A (ja) * 1981-12-28 1983-07-05 Yamanouchi Pharmaceut Co Ltd 「お」−(1−イミダゾリル)アルキルオキシ(またはチオ)ベンゼン誘導体
JPH0222752B2 (ja) * 1981-12-28 1990-05-21 Yamanouchi Pharma Co Ltd
JPH01125372A (ja) * 1988-09-12 1989-05-17 Yamanouchi Pharmaceut Co Ltd イミダゾリルアルキルオキシベンゼン誘導体
JPH0223547B2 (ja) * 1988-09-12 1990-05-24 Yamanouchi Pharma Co Ltd

Also Published As

Publication number Publication date
FI793868A (fi) 1980-06-14
ZA796708B (en) 1981-08-26
NZ192360A (en) 1982-02-23
IT1194900B (it) 1988-09-28
YU301879A (en) 1983-01-21
FR2444031A1 (fr) 1980-07-11
SE444937B (sv) 1986-05-20
NO153135B (no) 1985-10-14
FI70888B (fi) 1986-07-18
DE2950019A1 (de) 1980-07-10
ES486782A0 (es) 1980-12-16
FR2444031B1 (ja) 1983-06-10
GB2038821B (en) 1982-12-08
IL58917A0 (en) 1980-03-31
GB2038821A (en) 1980-07-30
PL220351A1 (ja) 1980-12-01
PL134005B1 (en) 1985-07-31
JPS585197B2 (ja) 1983-01-29
NL177749B (nl) 1985-06-17
ATA783379A (de) 1983-07-15
CA1108137A (en) 1981-09-01
PT70571A (en) 1980-01-01
US4602016A (en) 1986-07-22
US4636500A (en) 1987-01-13
GR73003B (ja) 1984-01-24
KR830001243B1 (ko) 1983-06-27
CS216517B2 (en) 1982-11-26
IE792403L (en) 1980-06-13
AU517892B2 (en) 1981-09-03
NO153135C (no) 1986-01-22
NL7908899A (nl) 1980-06-17
DK471479A (da) 1980-06-14
FI70888C (fi) 1986-10-27
KR830001242A (ko) 1983-04-29
AR227637A1 (es) 1982-11-30
BE880584A (fr) 1980-06-12
NL177749C (nl) 1985-11-18
IT7941669A0 (it) 1979-12-11
SE7910204L (sv) 1980-06-14
CH644597A5 (de) 1984-08-15
IL58917A (en) 1984-03-30
DD147943A5 (de) 1981-04-29
HU183016B (en) 1984-04-28
IE49318B1 (en) 1985-09-18
SU878195A3 (ru) 1981-10-30
NO794069L (no) 1980-06-16
ES8101556A1 (es) 1980-12-16
EG14227A (en) 1983-12-31
LU81985A1 (fr) 1980-04-22
AU5372579A (en) 1980-06-19
AT373879B (de) 1984-02-27
PH15056A (en) 1982-06-03

Similar Documents

Publication Publication Date Title
JPS5585572A (en) Nn*phenoxyalkyl*imidazole compound
GB2025946B (en) Imidazole derivative
JPS54145665A (en) Imidazole derivative
JPS54119486A (en) 66substituted thiaaaza compound
GB2031408B (en) Imidazole derivatives
GB2044754B (en) Imidazoles
JPS5592393A (en) Aminoorganosiliconacylamino compound
JPS5536475A (en) Prostanoid compound
GB2030563B (en) Imidazole derivatives
GB2016452B (en) Imidazole compounds
GB2025999B (en) Bistrialkoxysiloxy - silane compound
JPS54163582A (en) 22phenoxyy55 trifluoromethypiridine compound
GB2014575B (en) Substituted 2phenylimino imidazolidines
JPS54138524A (en) Boronnsilicon compound
JPS54160397A (en) Antiirhinouiruse compound
AU4549679A (en) Substituted imidazole compounds
JPS54138522A (en) Sulfonateeorganosilanol compound
AU5241179A (en) 1-phosphorylated-2-(phenoxyalkyl)-2-imidazoline derivatives
JPS54128538A (en) 44nitroo22trichlormethyllphenyldisulfide compound
JPS5536471A (en) Spiroketaline compound
JPS54125625A (en) 33hydroxybenzyl compound
JPS54141766A (en) Antiiinflammatory compound
NZ191297A (en) 1-iminomethylene-substituted-2-(phenoxyalkyl)-2-imidazoline derivatives insecticidal compositions
JPS5559193A (en) Bblactam compound
JPS554400A (en) Hindereddphenol compound